MK-677: 64 published COA source records
94 studies on MK-677 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 64 published MK-677 COA source records from third-party laboratories, covering 30 publicly attributable vendor identities. Across 14 records with positive numeric purity, the arithmetic mean is 98.55%. 0 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 0 positive purity results are below 90%; 5 records report measured amount more than 10% below the label. The latest recorded test date is 2026-09-11. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
MK-677: published third-party laboratory evidence
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-09-11. Aggregate calculated: 2026-09-26T10:34:26.608327+00:00. Calculation time is not a laboratory observation date.
Within that total, 23 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Top 3 vendor evidence profiles for MK-677
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 4 | 99.68% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → | |
| #2 | 2 | 99.65% | 0 of 2 (0.0%) 0 0% / not detected · 0 wrong compound | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #109314 · #109313 · #109162 · #109161 · #102520 · #102435
MK-677 studies and clinical research
-
Growth Hormone and IGF-1 axis implicated in brain regeneration across dementia, TBI, and stroke
If the systematic review confirms significant neuroregenerative potential for Growth Hormone (GH) and the `GH-IGF-1` axis, it could **redefine therapeutic strategies for devastating neurological conditions** like **de…
-
Performance-Enhancing Compounds Linked to Rare Spontaneous Splenic Rupture
This case report highlights a critical, rare, and potentially life-threatening complication associated with the use of performance-enhancing compounds. It underscores the importance for clinicians to consider ASR in p…
-
MK-0677 Trial Explores Potential for Alzheimer's Disease Treatment
Alzheimer's Disease remains a significant unmet medical need, and exploring novel therapeutic avenues is crucial. MK-0677, known as a growth hormone secretagogue (a compound that stimulates the secretion of growth hor…
-
Early Trial of MK0677 for Sarcopenia After Hip Fracture Terminated
-
Oral MK-677 Explored for Body Composition and Function in Older Adults
The potential for an oral GH secretagogue like MK-677 to restore youthful GH and IGF-I levels in older adults holds significant promise for combating age-related decline. If successful, this intervention could improve…
-
Ibutamoren Pilot Study Investigates Impact on Nonalcoholic Fatty Liver Disease
The prevalence of NAFLD and NASH is alarmingly high, and effective pharmacological treatments are scarce, making the exploration of new therapies critical. Positive findings from this pilot study could position Ibutam…
-
MK-0677 Study on Lean Body Mass in Advanced Kidney Disease Withdrawn
The withdrawal of this study means a significant opportunity was missed to explore a potential therapeutic avenue for muscle wasting in advanced CKD. Sarcopenia in CKD patients is a major predictor of morbidity and mo…
-
Oral MK-677 Boosts Growth Hormone, Lean Mass, and Metabolism in Obese Adults
-
MK-0677 Activates Specific Brain Neurons to Boost Growth Hormone Release
This research provides crucial, mechanistic insight into the direct neural targets of nonpeptide growth hormone secretagogues like MK-0677. Understanding how these compounds specifically activate neurons in the arcuat…
-
Human Brain and Pituitary Glands Possess Specific Receptors for GH Secretagogues
Why It Matters This study provides the first definitive evidence for specific, high-affinity GH secretagogue receptors in key human tissues, fundamentally advancing our understanding of how these compounds exert their…
-
Oral MK-677 Boosts Bone Turnover in Obese Young Men
This research highlights that MK-677 actively engages bone metabolism, accelerating both the building and breakdown phases. This dual effect suggests that while it stimulates bone activity, the net impact on bone mine…
-
Orally Active Growth Hormone Secretagogues: Current Status and Future Clinical Use
-
New Oral Peptidomimetics Potently Stimulate Growth Hormone Release
The discovery of potent, orally active Growth Hormone (GH) secretagogues like compound 18 is highly significant because it offers a non-invasive alternative to injectable peptide-based therapies. Such compounds could …
-
New Spiropiperidine Compounds Show Potent Growth Hormone Secretagogue Activity
The discovery of spiro(3H-1-benzopyran-2,3-piperidine), exhibiting low nanomolar potency, represents a significant breakthrough in the ongoing search for novel growth hormone secretagogues. This compound's high activi…
-
New Growth Hormone Secretagogues Show Promise for Thalassemia Treatment
This early review was pivotal in identifying a novel therapeutic strategy for addressing growth and endocrine complications in thalassemia. By proposing the use of GH secretagogues, the authors opened a new direction …
-
Oral MK-0677 Boosts IGF-I in Dogs via Pituitary Gland
This research is significant because it definitively establishes the pituitary-dependent mechanism of MK-0677. Understanding this mechanism is crucial for developing and safely utilizing growth hormone secretagogues, …
-
Systemic GH or MK-0677 Does Not Alter Canine Brain GH/IGF-1 Levels
This finding is significant because it suggests that systemic administration of GH or GH secretagogues may not directly influence GH/IGF-1 signaling within the brain, at least not via increased CSF concentrations. Thi…
-
C-Terminal Modifications Boost Potency of Growth Hormone Secretagogue NN703
This research highlights the significant potential of structural modifications to enhance the pharmacological profile of existing GHS. Identifying more potent analogues like NN703-S12 could lead to the development of …
-
MK-677 in Obese Subjects: Impact on Lipoproteins, Not Lipoprotein(a)
This research highlights that MK-677 can significantly modulate lipoprotein profiles in obese individuals, demonstrating its potential metabolic activity beyond just growth hormone stimulation. The observed reductions…
-
MK-677 Boosts Bone Turnover in Older Adults, Suggesting Bone Health Benefits
MK-677's ability to increase bone turnover markers suggests its potential role in combating age-related bone loss and improving overall bone health. While an initial increase in both formation and resorption might see…
-
Pituitary Tumors Express Functional Receptors for Growth Hormone Secretagogues
This research provides compelling evidence that human pituitary adenomas express functional growth hormone secretagogue receptors, which can directly influence hormone secretion. This discovery is crucial because it s…
-
Growth Hormone Secretagogues Alter Brain Gene Expression in Rats
This study provides crucial insights into the neurobiological mechanisms underlying chronic GHS action, particularly their influence on hypothalamic circuits regulating energy balance. The observed upregulation of ore…
-
GHRH and Morphine Modulate Growth Hormone Secretagogue Action in Rat Brain
This research highlights the complex neuroendocrine regulation of growth hormone secretagogue action within the hypothalamus. Understanding these interactions could be crucial for developing more targeted therapies fo…
-
MK-677 Boosts Growth Hormone But Decouples Leptin from Body Fat
This research highlights a novel mechanism by which MK-677 may influence metabolic pathways, specifically by altering the tightly regulated relationship between leptin and body fat. Understanding this discrepancy is c…
-
Unraveling Growth Hormone Releasing Substances and Their Receptor Mechanisms
This comprehensive review was instrumental in solidifying the understanding of the GHSR-1a pathway as a major regulator of GH secretion, independent of GHRH. The identification of orally active, non-peptidic GHS like …
-
Growth Hormone Secretagogues: Beyond Growth, Unveiling Diverse Human Effects
This review significantly expanded the understanding of GHS pharmacology, moving beyond their traditional role in GH deficiency. The identification of diverse non-endocrine actions, such as effects on appetite, metabo…
-
Growth Hormone Secretagogues Show Diverse Effects Across Multiple Organ Systems
This comprehensive review underscores the broad therapeutic potential of GHS across multiple organ systems and conditions. The observed benefits, from cardioprotection and growth promotion to metabolic improvements an…
-
Growth Hormone Secretagogues: Charting Their Clinical Potential in 2000
This landmark review fundamentally reshaped the understanding of GH modulation, establishing GHSs as a powerful and physiologically relevant therapeutic strategy. By stimulating endogenous GH, GHSs offered a pathway t…
-
Growth Hormone Secretagogues Activate Brain Regions Through Novel Non-Noradrenergic Pathways
This research significantly advances our understanding of how growth hormone secretagogues (GHS) exert their effects on the brain, revealing a novel, non-noradrenergic signaling pathway. This discovery is crucial beca…
-
Advanced Chromatography Developed to Separate Novel Growth Hormone Secretagogue Compounds
This research provides crucial analytical and preparative separation techniques essential for the development of new growth hormone secretagogue drugs. By enabling the purification of individual diastereomers, it allo…
-
Growth Hormone-Releasing Peptides Show Promise for Heart Health
This review critically highlights the therapeutic potential of GHRPs beyond their established GH-releasing properties, suggesting they could be novel pharmacological agents for treating various cardiovascular diseases…
-
Uncovering Key Drug Opportunities to Combat Aging and Neurodegenerative Diseases
This review was crucial in its time for mapping out nascent drug development pathways, providing a roadmap for future research. The identification of targets like growth hormone secretagogue receptor agonists and Nurr…
-
Adenosine Discovered as a Novel Agonist for Growth Hormone Secretagogue Receptor
This discovery fundamentally expands our understanding of GHSR regulation beyond ghrelin, suggesting a broader physiological role for this receptor. It implies that adenosine, a ubiquitous signaling molecule involved …
-
Growth Hormone Secretagogues: How They Work and Their Role in Aging
The findings suggest that GHS represent a promising therapeutic strategy for combating age-related decline in GH and IGF-1, potentially improving body composition and overall vitality in older adults. By stimulating e…
-
Adenosine Discovered as Natural Regulator of Growth Hormone Receptor
The study successfully identified adenosine as a partial agonist of the GHS-R, meaning it can activate the receptor but not to its full potential. Activation of GHS-R by adenosine was significantly inhibited by select…
-
Growth Hormone Secretagogue Receptors Discovered in Diverse Human Peripheral Tissues
This groundbreaking research significantly expands our understanding of GHS physiology, indicating that these compounds, and potentially the endogenous ligand ghrelin, have direct actions on multiple peripheral organs…
-
Combination of MK-677 and Alendronate Shows Superior Bone Density Gains in Osteoporosis
This study's findings are profoundly significant as they demonstrate that combining an antiresorptive agent like alendronate with a growth hormone secretagogue such as MK-677 can yield superior improvements in bone mi…
-
Ghrelin Receptors Found in Breast Cancer, May Inhibit Tumor Growth
-
Ghrelin Receptors Discovered in Human Hypothalamus and Pituitary Gland
This study provides critical direct evidence for the presence of ghrelin receptors in key human brain regions, specifically the hypothalamus and pituitary gland, which are central to regulating appetite, energy homeos…
-
Growth Hormone and Secretagogues: Impact on Bone Health Explored
This review underscores the critical role of the GH/IGF-1 axis in maintaining bone health and highlights the therapeutic potential of both GH and GHSs for bone disorders. The development of GHSs, which stimulate the b…
-
Unraveling the Growth Hormone Secretagogue Receptor Family and Its Ligands
This foundational review consolidated critical knowledge about the GHS-R system, providing a robust framework that significantly influenced subsequent research and drug discovery efforts. It highlighted the immense po…
-
Oral Ibutamoren Effectively Boosts Growth Hormone in Deficient Children
-
Novel Small Molecules Mimic Ghrelin to Potently Activate Growth Hormone Receptor
-
Endothelial Cells Modulate Hexarelin's Contractile Effects in Rat Hearts
This research is significant because it highlights the complex interplay between hexarelin and different cardiac cell types, specifically emphasizing the often-overlooked role of endothelial cells in mediating drug ef…
-
New Oral Compound SM-130686 Potently Boosts Growth Hormone in Rats
This study highlights SM-130686 as a potent, selective, and orally active growth hormone secretagogue. Its ability to significantly boost GH levels and improve lean body mass in an animal model suggests considerable t…
-
Novel Oxindole Derivative Potently Stimulates Growth Hormone, Shows Oral Activity
The identification of SM-130686 (37S) represents a significant step forward, as it is an orally active, highly potent growth hormone secretagogue with a favorable pharmacokinetic profile in rats. Its ability to induce…
-
Peptidyl GH Secretagogues Show Promise in Halting Lung Cancer Cell Growth
This research highlights a novel and potentially significant role for synthetic peptidyl GH secretagogues beyond their traditional endocrine functions, suggesting they could be repurposed as direct anticancer agents. …
-
Ghrelin and Des-Acyl Ghrelin Protect Heart Cells from Death
-
Ghrelin: A Multifaceted Peptide Beyond Just Growth Hormone Regulation
This comprehensive review highlights ghrelin's multifaceted nature, demonstrating it is far more than just a GH secretagogue. Understanding ghrelin's broad actions opens new avenues for therapeutic development and dru…
-
Capromorelin: A Novel Oral Growth Hormone Secretagogue for Musculoskeletal Frailty
The discovery of capromorelin represents a significant advancement in the development of orally active Growth Hormone Secretagogues (GHSs). Its excellent bioavailability and oral activity directly address a major hurd…
Research tools
Free, no account — handy when you're working with MK-677.
